The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Priority Review of a new drug application for revumenib in the treatment of patients with R/R KMT2Ar AML and ALL
On March 26, 2024, the U.S. Food and Drug Administration (FDA) granted revumenib, a first-in-class menin inhibitor, Priority Review for a New Drug Application that aims to treat patients with relapsed/refractory (R/R) KMT2A-rearranged acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Also, it has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 26, 2024. This is as a result of positive data from the AUGMENT-101 trial (NCT04065399).
AUGMENT-101 trial1
AUGMENT-101 investigated revumenib for the treatment of adult and pediatric patients with KMT2Ar AML and ALL. The study met its primary endpoint and had positive results from secondary endpoints (Figure 1).
Figure 1. Primary and secondary endpoints at the interim analysis stage of AUGMENT-101*
CR/CRh, complete response/complete response with partial hematologic recovery; MRD, minimal residual disease; OR, overall response.
*Adapted from Syndax.1
†Patients included who achieved a CR/CRh and were assessed for MRD.
‡Patients included from the efficacy-evaluable subgroup who achieved an overall response.
Conclusion
Priority Review of this New Drug Application could provide an alternative treatment option for patients who have R/R KMT2A-rearranged AML and ALL. This will address the unmet clinical need for patients with ALL and AML after first-line treatment relapse.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content